Showing 931-940 of 1226 results for "".
- Ikerian and RetinAI Secure $8M Financing to Drive AI Healthcare Innovationhttps://modernod.com/news/ikerian-and-retinai-secure-8m-financing-to-drive-ai-healthcare-innovation/2482494/Switzerland-based Ikerian AG and its subsidiary RetinAI US, announced the successful first close of their Series B financing round, securing USD $8 million (CHF 6.73 million). With the newly secured funding, Ikerian said it is set to fast-track the development of its flagship produ
- Bausch + Lomb Acquires Diagnostic Company Trukera Medicalhttps://modernod.com/news/bausch-lomb-acquires-diagnostic-company-trukera-medical/2482368/Bausch + Lomb announced it has acquired US-based privately held ophthalmic medical diagnostic company Trukera Medical. Financial terms of the deal were not disclosed. An affiliate of B+L acquired Trukera from its private equity owner, AccelMed Partners, and other shareholders. 
- Beacon Therapeutics Raises Funds to Advance Development of Its Ophthalmic Gene Therapieshttps://modernod.com/news/beacon-therapeutics-raises-funds-to-advance-development-of-its-ophthalmic-gene-therapies/2482341/Beacon Therapeutics announced it has raised $170 million in Series B funding, which will be used to support the continued clinical development of Beacon’s lead asset, AGTC-501, for X-linked retinitis pigmentosa (XLRP; laruparetigene zovaparvovec) and generate phase 1/2 clinical trial d
- FDA Accepts Eluminex Biosciences' IND Application for Trispecific Fusion Antibody for DMEhttps://modernod.com/news/fda-accepts-eluminex-biosciences-ind-application-for-trispecific-fusion-antibody-for-dme/2482259/Eluminex Biosciences announced the acceptance of its EB-105 IND application to the FDA. EB-105 is a novel trispecific fusion antibody targeting VEGF-A (and isomers), VEGF-B, placental growth factor (PlGF), angiopoetin-2 (Ang-2), and interleukin-6 receptor (IL-6R) for the treatment of DM
- Melt Pharmaceuticals Completes Stock Refinancing to Support Further Development of MELT-300https://modernod.com/news/melt-pharmaceuticals-completes-stock-refinancing-to-support-further-development-of-melt-300/2482198/Melt Pharmaceuticals announced the completion of its Series B Preferred Stock financing of approximately $24 million from new and existing investors. The capital raised will primarily support the further development of MELT-300, including the MELT-300 phase 3 program. MELT-300, a n
- Pandorum Technologies Secures $11 Million Investment to Advance its Regenerative Therapy for Corneal Blindness to Clinical Phasehttps://modernod.com/news/pandorum-technologies-secures-11-million-investment-to-advance-its-regenerative-therapy-for-corneal-blindness-to-clinical-phase/2482168/Pandorum Technologies announced the closure of a pre-Series B funding round, securing $11 million in investment to progress toward the first-in-human study of its flagship product, Kuragenx ("Liquid Cornea") to treat corneal blindness. The funding will also allow the
- iSTAR Medical Continues European Expansion with First MINIject Surgeries in the Netherlandshttps://modernod.com/news/istar-medical-continues-european-expansion-with-first-miniject-surgeries-in-the-netherlands/2482027/iSTAR Medical announced the successful first implantations of MINIject, the company’s bio-integrating, minimally-invasive glaucoma surgery (MIGS) device, in the Netherlands. Patients were successfully implanted at the University Eye Clinic of the Maastricht University Medical Center+ b
- Bausch + Lomb Launches enVista Aspire Monofocal and Toric IOLshttps://modernod.com/news/bausch-lomb-launches-envista-aspire-monofocal-and-toric-iols/2481897/Bausch + Lomb announced the launch of the enVista Aspire monofocal and toric IOLs in the United States. The enVista Aspire IOLs featured B+L's Intermediate Optimized (IO) optics, which are designed for a broader depth of focus, with the benefits of the enVista platform to address patient
- Allotex Secures Funding for Allogeneic Presbyopia Inlayshttps://modernod.com/news/allotex-secures-funding-for-allogeneic-presbyopia-inlays/2481717/Allotex and SpA announced the first close of its $30 million Series B financing to support the further development of its technology for the treatment of refractive errors. The investment was driven by 4-year data on presbyopia and hyperopia treatments, confirming significant impro
- Myra Vision Announces Funding to Advance Calibreye Surgical Treatment for Glaucoma Patientshttps://modernod.com/news/myra-vision-raises-money-to-advance-calibreye-surgical-treatment-for-glaucoma-patients/2481694/Myra Vision, which is a Shifamed portfolio company, announced the closing of its $25 million Series B financing to further product development, scale manufacturing capabilities, and support first-in-human investigation of the company's Calibreye System, a novel treatm